Enliven Therapeutics, Inc. (ELVN)
41.39
-0.13
(-0.31%)
USD |
NASDAQ |
Oct 26, 11:24
Enliven Therapeutics Enterprise Value : 2.148B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.148B |
| October 22, 2026 | 2.178B |
| October 21, 2026 | 2.170B |
| October 20, 2026 | 2.128B |
| October 19, 2026 | 1.941B |
| October 16, 2026 | 1.840B |
| October 15, 2026 | 1.987B |
| October 14, 2026 | 1.984B |
| October 13, 2026 | 1.999B |
| October 12, 2026 | 2.098B |
| October 09, 2026 | 2.108B |
| October 08, 2026 | 2.083B |
| October 07, 2026 | 2.136B |
| October 06, 2026 | 2.211B |
| October 05, 2026 | 2.437B |
| October 02, 2026 | 2.547B |
| October 01, 2026 | 2.491B |
| September 30, 2026 | 2.464B |
| September 29, 2026 | 2.513B |
| September 28, 2026 | 2.477B |
| September 25, 2026 | 2.384B |
| September 24, 2026 | 2.415B |
| September 23, 2026 | 2.483B |
| September 22, 2026 | 2.636B |
| September 21, 2026 | 2.686B |
| Date | Value |
|---|---|
| September 18, 2026 | 2.729B |
| September 17, 2026 | 2.787B |
| September 16, 2026 | 2.704B |
| September 15, 2026 | 3.015B |
| September 14, 2026 | 3.093B |
| September 11, 2026 | 3.085B |
| September 10, 2026 | 3.225B |
| September 09, 2026 | 3.315B |
| September 08, 2026 | 3.455B |
| September 04, 2026 | 3.452B |
| September 03, 2026 | 3.476B |
| September 02, 2026 | 3.429B |
| September 01, 2026 | 3.345B |
| August 31, 2026 | 3.347B |
| August 28, 2026 | 3.345B |
| August 27, 2026 | 3.538B |
| August 26, 2026 | 3.565B |
| August 25, 2026 | 3.575B |
| August 24, 2026 | 3.586B |
| August 21, 2026 | 3.488B |
| August 20, 2026 | 3.422B |
| August 19, 2026 | 3.457B |
| August 18, 2026 | 3.507B |
| August 17, 2026 | 3.467B |
| August 14, 2026 | 3.415B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Definium Therapeutics, Inc. | 3.745B |
| Cocrystal Pharma, Inc. | 12.20M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| Arvinas, Inc. | -83.01M |
| Fulcrum Therapeutics, Inc. | -32.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.48M |
| Total Expenses (Quarterly) | 32.48M |
| EPS Diluted (Quarterly) | -0.4909 |
| Earnings Yield | -4.03% |
| Normalized Earnings Yield | -4.031 |